Cognition in patients with neuromyelitis optica spectrum disorders: A prospective multicentre study of 217 patients (CogniNMO-Study)

Mult Scler. 2023 Jun;29(7):819-831. doi: 10.1177/13524585231151212. Epub 2023 Feb 14.

Abstract

Background: There is limited and inconsistent information on the prevalence of cognitive impairment in neuromyelitis optica spectrum disorders (NMOSD).

Objective: To assess cognitive performance and changes over time in NMOSD.

Methods: This study included data from 217 aquaporin-4-IgG-seropositive (80%) and double-seronegative NMOSD patients. Cognitive functions measured by Symbol Digit Modalities Test (SDMT), Paced Auditory Serial-Addition Task (PASAT), and/or Multiple Sclerosis Inventory Cognition (MuSIC) were standardized against normative data (N = 157). Intraindividual cognitive performance at 1- and 2-year follow-up was analyzed. Cognitive test scores were correlated with demographic and clinical variables and assessed with a multiple linear regression model.

Results: NMOSD patients were impaired in SDMT (p = 0.007), MuSIC semantic fluency (p < 0.001), and MuSIC congruent speed (p < 0.001). No significant cognitive deterioration was found at follow-up. SDMT scores were related to motor and visual disability (pBon < 0.05). No differences were found between aquaporin-4-IgG-seropositive and double-seronegative NMOSD.

Conclusions: A subset of NMOSD patients shows impairment in visual processing speed and in semantic fluency regardless of serostatus, without noticeable changes during a 2-year observation period. Neuropsychological measurements should be adapted to physical and visual disabilities.

Keywords: Neuromyelitis optica spectrum disorders; cognition; cognitive neuropsychology; neuroimmunology.

Publication types

  • Multicenter Study

MeSH terms

  • Aquaporin 4
  • Autoantibodies
  • Cognition
  • Humans
  • Immunoglobulin G
  • Multiple Sclerosis*
  • Neuromyelitis Optica* / complications
  • Neuromyelitis Optica* / epidemiology
  • Prospective Studies

Substances

  • Aquaporin 4
  • Immunoglobulin G
  • Autoantibodies